Replies to post #17845 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>Why no ATryn sales in Europe?<

I believe the answer is as stated in #msg-33917434:

Leo priced ATryn too high to compete effectively against the plasma-derived products in Europe. Leo did this to maintain the opportunity for premium pricing in the DIC/sepsis indication, but they carried the idea too far and killed off whatever modest sales might have occurred in the HD indication.